Mats Brune

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2293776/publications.pdf Version: 2024-02-01



MATS ROLINE

#	Article	IF	CITATIONS
1	Iron Absorption from Bread in Humans: Inhibiting Effects of Cereal Fiber, Phytate and Inositol Phosphates with Different Numbers of Phosphate Groups. Journal of Nutrition, 1992, 122, 442-449.	2.9	273
2	Inositol phosphates with different numbers of phosphate groups influence iron absorption in humans. American Journal of Clinical Nutrition, 1999, 70, 240-246.	4.7	240
3	Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood, 2006, 108, 88-96.	1.4	226
4	Inhibition of haem-iron absorption in man by calcium. British Journal of Nutrition, 1993, 69, 533-540.	2.3	141
5	Bioavailability in Man of Iron in Human Milk and Cow's Milk in Relation to Their Calcium Contents. Pediatric Research, 1992, 31, 524-527.	2.3	93
6	Histamine Protects T Cells and Natural Killer Cells Against Oxidative Stress. Journal of Interferon and Cytokine Research, 1999, 19, 1135-1144.	1.2	81
7	Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91phox expression and the PARP-1/PAR pathway of apoptosis. Blood, 2012, 119, 5832-5837.	1.4	75
8	Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000–2011. Haematologica, 2017, 102, 1683-1690.	3.5	65
9	The HLA-B â^'21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia. Blood, 2019, 133, 1479-1488.	1.4	50
10	A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study. Biology of Blood and Marrow Transplantation, 2018, 24, 1243-1249.	2.0	49
11	Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy. Cancer Immunology, Immunotherapy, 2017, 66, 1473-1484.	4.2	45
12	Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells. Haematologica, 2012, 97, 1904-1908.	3.5	44
13	Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period. Blood, 2019, 134, 1558-1561.	1.4	38
14	Results of riskâ€adapted therapy in acute myeloid leukaemia. A longâ€term populationâ€based followâ€up study. European Journal of Haematology, 2009, 83, 99-107.	2.2	35
15	NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance. Oncotarget, 2015, 6, 42569-42574.	1.8	35
16	Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia. Oncolmmunology, 2016, 5, e1041701.	4.6	34
17	Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry. Bone Marrow Transplantation, 2019, 54, 1764-1774.	2.4	33
18	Genital Chronic Graft-versus-Host Disease in Females: A Cross-Sectional Study. Biology of Blood and Marrow Transplantation, 2014, 20, 806-811.	2.0	32

Mats Brune

#	Article	IF	CITATIONS
19	Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting. Biology of Blood and Marrow Transplantation, 2019, 25, 1770-1778.	2.0	25
20	NOX2-dependent immunosuppression in chronic myelomonocytic leukemia. Journal of Leukocyte Biology, 2017, 102, 459-466.	3.3	21
21	A prospective study of female genital chronic graftâ€versusâ€host disease symptoms, signs, diagnosis and treatment. Acta Obstetricia Et Gynecologica Scandinavica, 2018, 97, 1122-1129.	2.8	19
22	Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity. Blood Advances, 2022, 6, 2723-2730.	5.2	19
23	Minimal residual disease assessed with deep sequencing of <i>NPM1</i> mutations predicts relapse after allogeneic stem cell transplant in AML. Leukemia and Lymphoma, 2019, 60, 409-417.	1.3	15
24	Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation. Haematologica, 2022, 107, 1479-1482.	3.5	15
25	Low response rate to <scp>ATG</scp> â€based immunosuppressive therapy in very severe aplastic anaemia — A Swedish nationwide cohort study. European Journal of Haematology, 2018, 100, 613-620.	2.2	13
26	Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype. Human Vaccines and Immunotherapeutics, 2020, 16, 109-111.	3.3	13
27	Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia. Oncotarget, 2016, 7, 7586-7596.	1.8	13
28	High Graft-versus-Host Disease-Free, Relapse/Rejection-Free Survival and Similar Outcome of Related and Unrelated Allogeneic Stem Cell Transplantation for Aplastic Anemia: A Nationwide Swedish Cohort Study. Biology of Blood and Marrow Transplantation, 2019, 25, 1970-1974.	2.0	11
29	Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib. Blood, 2016, 128, 4561-4561.	1.4	10
30	Cytomegalovirus Serostatus Affects Autoreactive NK Cells and Outcomes of IL2-Based Immunotherapy in Acute Myeloid Leukemia. Cancer Immunology Research, 2018, 6, 1110-1119.	3.4	8
31	Humoral immunity to tetanus, diphtheria and polio in adults after treatment for hematological malignancies. Vaccine, 2020, 38, 1084-1088.	3.8	5
32	Vaccination against tick-borne encephalitis (TBE) after autologous and allogeneic stem cell transplantation. Vaccine, 2021, 39, 1035-1038.	3.8	5
33	Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapseâ€preventive immunotherapy in acute myeloid leukaemia. British Journal of Haematology, 2020, 188, e49-e53.	2.5	4
34	Haemoglobin Köln as <i>de novo</i> mutations in Sweden: Diagnosis by PCR and specific enzymatic cleavage. European Journal of Haematology, 1994, 52, 156-161.	2.2	3
35	Reduced Intensity Conditioned Sibling Transplantation Versus No Transplant in Intermediate or High Risk Acute Myeloid Leukemia: A Prospective Multi-Center Study in Patients 50-70 Years in First Complete Remission and with at Least One Potential Sibling Donor (ClinTrialGov 00342316). Blood, 2018, 132, 205-205.	1.4	2
36	Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid Leukemia. Frontiers in Immunology, 2021, 12, 796072.	4.8	2

Mats Brune

#	Article	IF	CITATIONS
37	Impact of Conditioning on the Outcome of Allografting in Myelofibrosis with Myeloid Metaplasia: Better Survival with Reduced Intensity Approach in Patients ≥50 Years Blood, 2007, 110, 1095-1095.	1.4	0
38	Age-related trends in utilization and outcome of autologous haematopoietic cell transplantation for multiple myeloma Journal of Clinical Oncology, 2014, 32, 8592-8592.	1.6	0
39	Incidence and Outcome in Aplastic Anemia Diagnosed 2000-2011 - a Nationwide Swedish Registry Study. Blood, 2016, 128, 3905-3905.	1.4	0
40	Complete Remission after the First Cycle of Induction Chemotherapy Determines the Clinical Efficacy of Relapse-Preventive Immunotherapy in Acute Myeloid Leukemia. Blood, 2019, 134, 1318-1318.	1.4	0